Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dexcom (DXCM) EBITDA (2016 - 2026)

Dexcom has reported EBITDA over the past 17 years, most recently at $255.3 million for Q1 2026.

  • Quarterly EBITDA rose 90.95% to $255.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Mar 2026, up 63.36% year-over-year, with the annual reading at $911.8 million for FY2025, 51.97% up from the prior year.
  • EBITDA was $255.3 million for Q1 2026 at Dexcom, down from $323.0 million in the prior quarter.
  • Over five years, EBITDA peaked at $323.0 million in Q4 2025 and troughed at $41.3 million in Q1 2022.
  • The 5-year median for EBITDA is $152.0 million (2024), against an average of $162.1 million.
  • Year-over-year, EBITDA surged 20800.0% in 2022 and then fell 26.03% in 2024.
  • A 5-year view of EBITDA shows it stood at $125.4 million in 2022, then soared by 72.97% to $216.9 million in 2023, then decreased by 12.91% to $188.9 million in 2024, then skyrocketed by 70.99% to $323.0 million in 2025, then dropped by 20.96% to $255.3 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's EBITDA are $255.3 million (Q1 2026), $323.0 million (Q4 2025), and $242.5 million (Q3 2025).